Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$15.92 USD
-0.22 (-1.36%)
Updated May 23, 2024 04:00 PM ET
After-Market: $15.94 +0.02 (0.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Brokerage Reports
0 items in cart
Catalyst Pharmaceuticals, Inc. [CPRX]
Reports for Purchase
Showing records 141 - 160 ( 418 total )
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pandemic Impacts on Firdapse, With Further Upside and Pipeline Progress on Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q20 Recap - COVID-19 Headwinds Impacting Targets
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Firdapse Impetus in LEMS Stands to Benefit Even Further From Broader Pipeline Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Continued Firdapse Commercial Traction With key Pipeline Catalysts in the Near-Term; Reit Buy and $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Looking Ahead to 2020 Development With Anticipated MuSK-MG Topline Results; Reit Buy and $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department